Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 2
---
 to Purchase up to 13,677,354 Shares of Common Stock

Placement Agent Warrants to Purchase up to 210,420 Shares of Common Stock

Up to 20,901,802 Shares of Common Stock Issuable Upon Exercise of

Pre-Funded Warrants, Warrants and Placement Agent Warrants</div>

We are offering up to 7,014,028 shares (the “Shares”) of our common stock, par value $0.007 per share (the “Common Stock”), together with warrants (the “May 2025 Warrants”) to purchase up to 13,677,354 shares of Common Stock. The number of shares of Common Stock issuable upon exercise of the May 2025 Warrants and offered hereby is equal to 150% of the number of Shares and Pre-Funded Warrants, plus an additional 30% increase in the number of shares of Common Stock that would be issuable upon exercise of the May 2025 Warrants if a reverse stock split is effected prior to the expiration of the May 2025 Warrants(the “Reverse Stock Split Adjustment”) . This registration statement does not register the issuance of up to an additional 61,397,642 shares of Common Stock which are issuable upon exercise of the May 2025 Warrants pursuant to pursuant to the Anti-Dilution Adjustment (as defined below) contained therein. The assumed combined public offering price for each share of Common Stock and accompanying May 2025 Warrant to purchase one and one-half share of Common Stock is $0.499, which is equal to the last reported sale price of our Common Stock on the Nasdaq Capital Market (“Nasdaq” or the “Nasdaq Capital Market”) on April 25, 2025. Each share of our Common Stock is being sold together with one May 2025 Warrant to initially purchase one and one-half share of Common Stock.

The May 2025 Warrants will have an initial exercise price of $[*] per share (110% of the combined public offering price per share of Common Stock and accompanying May 2025 Warrant) and will be immediately exercisable, except that the issuance of shares of Common Stock upon exercise of the May 2025 Warrants pursuant to the Anti-Dilution Adjustment contained therein will be subject to the filing of an amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to increase our authorized number of shares of Common Stock to 350,000,